Posted inInfectious Diseases news
Olorofim Offers a New Salvage Option for Drug‑Resistant Invasive Fungal Disease — Phase 2b Results
Phase 2b data show olorofim has activity and acceptable tolerability in patients with invasive fungal disease and limited options, including azole‑resistant Aspergillus and intrinsically resistant moulds, supporting further controlled studies.
